America First Investment Advisors LLC Has $20.49 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

America First Investment Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 126,437 shares of the company’s stock after purchasing an additional 2,441 shares during the quarter. Johnson & Johnson makes up approximately 4.6% of America First Investment Advisors LLC’s investment portfolio, making the stock its 15th largest position. America First Investment Advisors LLC’s holdings in Johnson & Johnson were worth $20,490,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Meridian Financial Partners LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $1,626,000. Meridian Investment Counsel Inc. raised its holdings in Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after acquiring an additional 3,710 shares during the period. Sheaff Brock Investment Advisors LLC lifted its position in Johnson & Johnson by 137.2% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 43,568 shares of the company’s stock worth $7,061,000 after acquiring an additional 25,203 shares during the last quarter. Lmcg Investments LLC grew its position in shares of Johnson & Johnson by 32.7% in the third quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock valued at $14,125,000 after purchasing an additional 21,471 shares during the last quarter. Finally, WealthPlan Investment Management LLC increased its stake in shares of Johnson & Johnson by 7.3% during the third quarter. WealthPlan Investment Management LLC now owns 61,691 shares of the company’s stock worth $9,998,000 after purchasing an additional 4,174 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JNJ. Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup upped their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Trading Up 0.1 %

NYSE JNJ opened at $153.10 on Thursday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The business’s fifty day moving average is $160.59 and its 200 day moving average is $156.17. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market cap of $368.59 billion, a price-to-earnings ratio of 22.16, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.66 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.